Weight loss drug Wegovy flying off the shelves in the US: Report nextdigitalhealth.com

We know that weight loss drugs have become very popular but the extent to which they are in demand was not known earlier. Now, there is a report which says that Wegovy, the prescription weight loss drug, is experiencing unprecedented demand, leaving pharmacies and patients grappling with shortages. Developed by Novo Nordisk, Wegovy has become a beacon of hope for millions seeking to combat obesity, a condition affecting over 42% of American adults according to the Centers for Disease Control and Prevention (CDC).

Wegovy, approved by the FDA in 2021, stands out for its efficacy in facilitating significant weight loss through once-weekly injections. Its active ingredient, semaglutide, works by mimicking a hormone that targets areas of the brain involved in appetite regulation, thereby reducing hunger and caloric intake. Clinical trials have showcased remarkable results, with participants losing up to 15% of their body weight, a figure that starkly contrasts with the outcomes of diet and exercise alone.